[1] Liu W Z, Xie Y, Lu H, et al. Fifth Chinese national consensus report on the management of Helicobacter pylori infection[J]. Helicobacter, 2018, 23(2): e12475. [2] Xie C, Lu N H. Review: clinical management of Helicobacter pylori infection in China[J]. Helicobacter, 2015, 20(1): 1-10. [3] 蔡玲, 伊比然恨, 张玫, 等. 拉萨地区自然人群幽门螺杆菌感染的流行病学调查[J]. 中华消化杂志, 2018, 38(1): 2-6. [4] Malfertheiner P, Megraud F, O'Morain C A, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report[J]. Gut, 2017, 66(1): 6-30. [5] Zhou X Z, Zhu H Y, Zhu C P, et al. Helicobacter pylori infection and serum pepsinogen level with the risk of gastric precancerous conditions: a cross-sectional study of high-risk gastric cancer population in China[J]. J Clin Gastroenterol, 2021, 55(9): 778-784. [6] Basso D, Navaglia F, Brigato L, et al. Analysis of Helicobacter pylori vacA and cagA genotypes and serum antibody profile in benign and malignant gastroduodenal diseases[J]. Gut, 1998, 43(2): 182-186. [7] Tsutsumi R, Takahashi A, Azuma T, et al. Focal adhesion kinase is a substrate and downstream effector of SHP-2 complexed with Helicobacter pylori CagA[J]. Mol Cell Biol, 2006, 26(1): 261-276. [8] Shiota S, Matsunari O, Watada M, et al. Serum Helicobacter pylori CagA antibody as a biomarker for gastric cancer in east-Asian countries[J]. Future Microbiol, 2010, 5(12): 1885-1893. [9] McClain M S, Beckett A C, Cover T L. Helicobacter pylori vacuolating toxin and gastric cancer[J]. Toxins (Basel), 2017, 9(10): 316. [10] González C A, Figueiredo C, Lic C B, et al. Helicobacter pylori cagA and vacA genotypes as predictors of progression of gastric preneoplastic lesions: a long-term follow-up in a high-risk area in Spain[J]. Am J Gastroenterol, 2011, 106(5): 867-874. [11] 董欣红, 胡伏莲, 高文, 等. 免疫印迹法检测幽门螺杆菌分型的多中心研究[J]. 中华医学杂志, 2016, 96(4): 265-269. [12] 刘卫东, 美丽克扎提, 惠文佳, 等. 不同类型幽门螺杆菌感染与萎缩性胃炎进展的关系[J]. 中华消化杂志, 2018, 38(4): 222-225. |